Barry Ticho - Sep 3, 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Sep 3, 2024
Transactions value $
-$143,481
Form type
4
Date filed
9/5/2024, 04:20 PM
Previous filing
Aug 5, 2024
Next filing
Oct 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $6K +10K +402.41% $0.60 12.5K Sep 3, 2024 Direct
transaction STOK Common Stock Sale -$140K -9.4K -75.29% $14.92 3.09K Sep 3, 2024 Direct F1, F2
transaction STOK Common Stock Sale -$9.24K -600 -19.45% $15.41 2.49K Sep 3, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Stock Option (Right to Buy) Options Exercise $0 -10K -25% $0.00 30K Sep 3, 2024 Common Stock 10K $0.60 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.35 to $15.34 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3, below.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.35 to $15.47 per share, inclusive.
F4 This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.